Melanoma Drug Development Analysis: From First-in-Class to Best-in-Class?
LONDON, Sept. 18, 2014 /PRNewswire/ -- This report gives you a new and unique way of stratifying and analyzing the global melanoma pipeline and presents actionable analysis which allows you to discover:
* Where the competition is; Which targets and companies are setting the path?
* What is first-in-class in the melanoma pipeline?
* Is First-in-Class the Best-in-Class?
* Indication expansion opportunities
* Drug repositioning opportunities
* Which pathways are targeted, by what and how?
* Locate the right drugs to benchmark against and see were others may have succeeded or failed before you.
BioSeeker builds its analysis on a comprehensive base of 282 melanoma drugs from within the portfolio of 164 companies world-wide, from Ceased to Marketed. We have identified 226 drug targets, which we have organized into 187 drug target strategies and assessed them in melanoma.
Our pipeline analysis has five levels:
1. Target Atlas: Shows you how individual targets tie into different target strategies and their subsequent R&D progress.
2. First-in-Class to Best-in-Class: Shows you the progress and maturation of different target strategies. Identifies which target strategies are new and unique from one developmental stage to the next.
3. Compound Type: Shows you the competitive landscape of target strategies from a compound perspective, including crossover analysis of target strategies among different compound types.
4. Indication Selection: Shows the distribution and deployment of target strategies in melanoma.
5. Competive Landscape: Provides a cross-examination of each company's entire pipeline on the basis of its defined drug target strategies, including a Competitive Fall-Out analysis and a corporate pipeline ranking based on 15 parameters.
Our Analysis includes:
* Head-to-head target competing analysis
* Significant drug target overlap analysis
* Cross-sectional R&D profiling of individual drug targets.
* Competitive Fall-Out analysis of the entire company pipeline: Answering three core questions about each company's pipeline:
-Where are we?
- Where is our general and specific competition?
- What is the level of competition where we want to be?
* 15 parameter deep corporate pipeline ranking, including both internal and external pipeline factors.
The report serves as an external commercial advocate for your company's interest in the melanoma pipeline by:
* Better identifying benchmarking peers
* Providing rationale for in/out licensing decisions of drug candidates
* Performing proper drug due diligence
* Strategies for commercial planning
* Guiding Research & Development efforts
Download the full report: https://www.reportbuyer.com/product/1361166/
About Reporbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com
SOURCE ReportBuyer
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article